Company Information & Drug Savings for BeiGene, Ltd. Medications
BeiGene is a global biotechnology company focused on developing innovative cancer treatments. The company’s oncology portfolio includes Brukinsa (zanubrutinib), a BTK inhibitor for various blood cancers including mantle cell lymphoma, chronic lymphocytic leukemia (CLL), and Waldenström’s macroglobulinemia. BeiGene also develops Tislelizumab, a PD-1 inhibitor for solid tumors and hematological malignancies. The company combines global research capabilities with extensive clinical development expertise.
How to Contact Beigene, Ltd.
Phone
1-857-302-5555Medical Disclaimer
NowPatient has taken all reasonable steps to ensure that all material is factually accurate, complete, and current. However, the knowledge and experience of a qualified healthcare professional should always be sought after instead of using the information on this page. Before taking any drug, you should always speak to your doctor or another qualified healthcare provider.
The information provided here about medications is subject to change and is not meant to include all uses, precautions, warnings, directions, drug interactions, allergic reactions, or negative effects. The absence of warnings or other information for a particular medication does not imply that the medication or medication combination is appropriate for all patients or for all possible purposes.
Experienced a Side Effect?
Report to Yellow Card (UK) or MedWatch (US)
